Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 4/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | CIT | O14578 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414535 | 0.91 | KDR (0.46) | KDRAURKAFLT1MET | |
| SCHEMBL11914994 | 0.90 | DHPS (0.45) | DHPSRETKDRBTKAURKA | |
| SCHEMBL4974499 | 0.90 | DHPS (0.44) | DHPSRETKDRBTKAURKA | |
| SCHEMBL4973733 | 0.85 | DHPS (0.52) | DHPSRETKDRMET | |
| SCHEMBL4975021 | 0.85 | KDR (0.48) | RETKDRFLT1METNPC1 | |
| SCHEMBL11914216 | 0.83 | KDR (0.40) | DHPSRETKDRAURKAAURKB | |
| SCHEMBL4977706 | 0.83 | KDR (0.49) | KDRMET | |
| SCHEMBL4972124 | 0.81 | KDR (0.47) | KDRAURKAFLT1MET | |
| SCHEMBL4971839 | 0.81 | RAB9A (0.45) | KDRMETNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4970611 | 0.80 | PDPK1 (0.42) | KDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | claimed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | claimed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1971604-B1 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-1971604-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | Amgen Inc. (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | DHPS 35/4885RET 1817/4885KDR 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.